Simultaneous detection and identification of
Helicobacter pylori and 3 major mutations
causing clarithromycin-resistance using multiplex real-time PCR
The prevalence of Helicobacter pylori (H. pylori) infection varies greatly among countries. In developing countries, it is over 70% while industrialized nations show prevalent from 20% to 50%1). Infection with H. pylori is considered a major cause of chronic gastritis and peptic ulcer disease2) and it is correlated with stomach cancer.
The “Triple Therapy” is first-line eradication therapy, which consists of a combination of Amoxicillin, Clarithromycin and a proton pump inhibitor3). However, clarithromycin resistance is increasing worldwide, and it has been considered as the main factor reducing about 30% of efficacy of H. pylori therapy4).
Allplex™ H. pylori & ClariR Assay is a multiplex real-time PCR assay that detects and identifies H. pylori and the most frequent point mutations (A2142G, A2143G and A2142C) responsible for clarithromycin resistance within the H. pylori 23S rRNA gene.
1) Liu Z, et al. BMC Microbiol. 2008;8:81
2) Cameron EA, et al. J Med Microbiol. 2004;53:535–8.
3) Glocker E, et al. Antimicrob. Agents Chemother. 2007, 51(1): 346-349
4) O’Connor A. Helicobacter 15 (Suppl. 1): 46–52
- H. pylori
- Internal Control (IC)
|- Gastric biopsy specimen*||- Stool|
|Allplex™ H. pylori & ClariR Assay||HC10200Y
If you are interested in finding more about this product,
please do not hesitate to contact us